RecruitingPhase 3NCT04808505
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
Studying Glycogen storage disease due to acid maltase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amicus Therapeutics
- Intervention
- Cipaglucosidase alfa(biological)
- Enrollment
- 36 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2023 – 2027
Study locations (14)
- University of Florida Clinical Research Center, Gainesville, Florida, United States
- The Emory Clinic, Atlanta, Georgia, United States
- Duke University Early Phase Research Unit, Durham, North Carolina, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- UPMC Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Utah, Clinical and Translational Sciences Institute, Salt Lake City, Utah, United States
- Universitätsklinikum Gießen und Marburg GmbH, Zentrum fur Kinderheilkunde und Jugendmedizin Abteilung fur Kinderneurologic, Sozialpadiatric und Epileptologie, Giessen, Germany
- Universitätsklinikum Heidelberg - Pädiatrisches Klinisch-Pharmakologisches Studienzentrum (paedKliPS), Heidelberg, Germany
- SphinCS GmbH, Höchheim, Germany
- Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin Albert-Schweitzer-Campus 1, Münster, Germany
- AOU Federico II, Naples, Italy
- Erasmus MC, Sophia Kinderziekenhuis, Rotterdam, Netherlands
- National Taiwan University Hospital, Taipei, Taiwan
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04808505 on ClinicalTrials.govOther trials for Glycogen storage disease due to acid maltase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07478172Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular DiseaseUniversity of Missouri-Columbia
- RECRUITINGPHASE1, PHASE2NCT07282847A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD)AskBio Inc
- RECRUITINGPHASE2NCT07123155Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)Shionogi
- RECRUITINGPHASE4NCT06666413China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPDGenzyme, a Sanofi Company
- RECRUITINGNCT06795152Rare Glycogen Storage Diseases Natural History StudyDuke University
- RECRUITINGPHASE1, PHASE2NCT06391736Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy DrugGeneCradle Inc
- RECRUITINGNCT06121011A Global Prospective Observational Registry of Patients With Pompe DiseaseAmicus Therapeutics
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06109948Study to Assess the Safety, Tolerability, PK and PD of ABX1100Aro Biotherapeutics
See all trials for Glycogen storage disease due to acid maltase deficiency →